Trial Profile
A single-center, open-label phase II clinical trial of apatinib treatment combined with pemetrexed plus platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Apr 2019 Status changed from recruiting to completed.
- 02 May 2018 New trial record